Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 3;8(6):1759091416674833. doi: 10.1177/1759091416674833

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2016

This article is distributed under the terms of the Creative Commons Attribution 3.0 License (http://www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 9. — Effect of hUCBSC-MO treatment on astrogliosis formation in ventral horn of spinal cord after injury. Intraperitoneal injection of MO (150 mg/kg) was started one day after injury and continued once a day for 14 days after injury. Intraspinal grafting of hUCBSCs was started 24 hr after injury. Data are represented as mean of GFAP-positive astrocytes ± SEM (n = 5–7) and analyzed by one-way ANOVA followed by post hoc Bonferroni’s multiple comparison test. ***p < .001 shows significant difference between SCI versus intact. ##p < .01, and ###p < .001 versus spinal cord injury. Φ shows significant difference between SCI-MO-hUCBSC and SCI-hUCBSC (p < .05). $$ shows significant difference between SCI-MO-hUCBSC and SCI-MO (p < .05, p < .01, and p < .001, respectively). Note. hUCBSCs = human umbilical cord blood stem cells; GFAP = glial fibrillary acidic protein; MO = Melissa officinalis; SCI = spinal cord injury; SEM = standard error of the mean; ANOVA = analysis of variance.